Does higher number of lymph nodes (LNs) excised during radical prostatectomy (RP) improve biochemical relapse-free survival (bRFS) in patients with pT2-3a/pN0 prostate cancer? This is an ASCO Meeting ...

PARIS, Sept 25 (Reuters) - Ipsen has submitted a six-month sustained version of its prostate cancer treatment Decapeptyl for marketing approval with European health authorities, the French drugmaker ...

This is a preview. Log in through your library . Abstract The effects of depot formulations of the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl (25 µg/day) for 30 days or LHRH ...

Once approved, Decapeptyl® 6-month formulation will be marketed by Debiopharm’s partners, such as Ipsen in most European Union countries. “This submission in Europe of our first 6-month-formulation ...

PARIS, Oct 13 (Reuters) - Ipsen has completed the marketing approval registration in nine European countries for a six-month sustained version of prostate cancer treatment Decapeptyl, the French ...

The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...

Ipsen (Euronext: FR0010259150; Paris: IPN) today announced the start of the filing process in Europe of the 6–month sustained release formulation of Decapeptyl ®, a luteinizing hormone releasing ...

The approval covers a six-month sustained-release version of Decapeptyl®, an LHRH agonist. Debiopharm and its European marketing partner, Ipsen, confirmed regulatory approval of its prostate cancer ...

Sustained-release LHRH agonist was recently cleared in multiple EU countries. Debiopharm and its European licensee, Ipsen, confirmed French regulatory clearance for the six-monthly sustained-release ...

The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...